Parexel International GmbH
Berlin, 14050, Germany
Location status: Recruiting
NCT Number: NCT07508020
The purpose of this clinical study is to look at if/how much NNC0487-0111 affects food intake, appetite and metabolism in participants with obesity when compared to placebo. There are 2 study treatments in this study. Participants will inject the study treatment under the skin of your stomach once a week. Participants will get either NNC0487-0111 (the treatment being tested) or Placebo (a treatment that has no active medicine in it). Which treatment participants will get is decided by chance.
Interested in participating?
Request Info18 year–64 year
All sexes
Interventional
Phase 1
Berlin, 14050, Germany
Location status: Recruiting
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Key Inclusion Criteria:
Key Exclusion Criteria:
NNC0487-0111 will be administered subcutaneously using PDS290 pre-filled pen-injectors into a skin fold on the abdomen.
Placebo matched to NNC0487-0111 will be administered subcutaneously using PDS290 pre-filled pen-injectors into a skin fold on the abdomen.
Time frame: From Baseline to Day 126
Measured as percentage change of energy.
Time frame: From Baseline to Day 182
Measured as percentage change of energy.
Time frame: From Baseline to Day 238
Measured as percentage change of energy.
Time frame: From Baseline to Day 126
Measured as kilojoules (kJ).
Time frame: From Baseline to Day 182
Measured as kJ.
Time frame: From Baseline to Day 238
Measured as kJ.
Time frame: From Baseline to Day 126
Measured as grams.
Time frame: From Baseline to Day 182
Measured as grams.
Time frame: From Baseline to Day 238
Measured as grams.
Time frame: From Baseline to Day 378
Measured as percentage change of energy.
Time frame: From Baseline to Day 378
Measured as kJ.
Time frame: From Baseline to Day 378
Measured as grams.
Time frame: From Baseline to Day 126
Measured as kJ.
Time frame: From Baseline to Day 182
Measured as kJ.
Time frame: From Baseline to Day 238
Measured as kJ.
Time frame: From Baseline to Day 378
Measured as kJ.
Time frame: From Day 19 to Day 131
Measured as percentage change of body weight.
Time frame: From Day 19 to Day 187
Measured as percentage change of body weight.
Time frame: From Day 19 to Day 243
Measured as percentage change of body weight.
Time frame: From Day 19 to Day 383
Measured as percentage change of body weight.
Contact information is provided by the study sponsor or research team.
Novo Nordisk A/S
Industry
Effect of Once-weekly Subcutaneous Administration of NNC0487-0111 on Energy Intake, Appetite and Postprandial Metabolism in Participants With Obesity - a Randomised, Placebo-controlled, Double Blinded Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06619041
Behavior, Body Weight
Aurora, Colorado, United States
View Trial DetailsNCT06858761
Body Weight, Nutrition Disorders
Bordeaux, France
View Trial DetailsNCT06374875
Body Weight, Digestive System Diseases
Phoenix, Arizona, United States
View Trial DetailsNCT06325722
Body Weight, Body Weight Changes
Bethesda, Maryland, United States
View Trial Details